Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Weight Loss 1Urologic Neoplasms 1Smoking Cessation 1Prostatic Neoplasms 1Neoplasms 1Gastrointestinal Neoplasms 1Fasting 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Surveys and Questionnaires 5Nivolumab 5pembrolizumab 3atezolizumab 3Radiosurgery 3pralsetinib 2pertuzumab 2cobimetinib 2cemiplimab 2amminedichloro(2-methylpyridine)platinum(II) 2alectinib 2Magnetic Resonance Spectroscopy 2Exercise 2Drug Therapy 2trastuzumab deruxtecan 1trametinib 1tepotinib 1talazoparib 1selpercatinib 1repotrectinib 1remune 1ponatinib 1pemigatinib 1pazopanib 1palbociclib 1osimertinib 1motexafin gadolinium 1montanide ISA 51 1itacitinib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Diet × Thoracic × Clear all
NCT03410641 2018-01-25

Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study

Oslo University Hospital

Completed
1,216 enrolled
GastrointestinalGenitourinaryThoracic

Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Urologic Neoplasms, Weight Loss, Smoking Cessation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡